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Non-alcoholic fatty liver disease (NAFLD) - a condition associated with the metabolic syndrome, has 
become common in an era of poor diet and reduced physical activity, affecting up to one in four 
adults1. Patients exhibit variability in the rate of liver disease progression but only a relative minority 
progress to cirrhosis and liver-related death.  However, NAFLD is also associated with increased 
morbidity and mortality from coronary heart disease (CHD), with emerging evidence implicating 
hepatic fibrosis (a progressive feature of NAFLD) in other vascular disorders such as ischaemic stroke 
2,3. Therefore, an important research question in the past decade has been to tease apart whether 
NAFLD independently increases the risk of CHD.  
Patients with NAFLD typically have multiple risk factors for CHD, including insulin resistance, 
dyslipidaemia, high blood pressure, and being overweight. Hepatocytes infiltrated with fat produce 
inflammatory cytokines, pro-thrombotic factors and adhesion molecules which have been associated 
with a further increase in cardiovascular disease risk4. Emerging cross-sectional and longitudinal 
evidence further identify associations between NAFLD and subclinical cardiovascular disease5. 
Regardless of causation, the association of NAFLD and CHD might have implications for 
cardiovascular risk prediction. However, to our knowledge the presence of NAFLD has yet to be 
evaluated for inclusion in risk prediction tools (e.g. QRISK2 and SCORE), some of which now 
include other non-cardiovascular co-morbidities such as rheumatoid arthritis6,7.  
However, a more challenging question is whether NAFLD itself plays a causal role in the 
development of CHD. Lauridsen and colleagues8 set out to answer this, replicating the graded 
observational associations between liver fat content and CHD. However, the observational association 
of NAFLD and CHD might occur because both share common risk factors rather than one causing the 
other. Mendelian randomization (MR) (Figure 1A) is an established epidemiological approach that 
can provide insight on causality.  MR uses genetic variants associated with an exposure to assess its 
causal effect on an outcome of interest. In the classic MR paradigm, genetic associations are free from 
confounding since they are assigned randomly at conception (according to Mendel’s second law) and 
reverse causation is precluded since the sequence of the germline is not modifiable by disease. MR 
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can be thought of as analogous to a randomized controlled trial (RCT) that uses naturally randomized 
genetic variation rather than randomized allocation to a treatment, as the ‘intervention’ (Figure 1B). A 
causal explanation for the observational association between liver fat and CHD detected by the 
authors was not supported by an MR analysis using a known NAFLD associated genetic variant 
(I148M in PNPLA3) as an instrumental variable. 
The current negative study does not come as a complete surprise. Some previous studies have 
suggested that only patients with the more severe, inflammatory liver phenotype (non-alcoholic 
steatohepatitis) rather than those with simple steatosis have an increased CHD mortality compared 
with a matched population9. Other robustly associated NAFLD variants in known genes (TM6SF2) 
have, perhaps counter intuitively, been found to be cardioprotective10. For example, a recent exome-
wide association study of plasma lipids in >300,000 individuals demonstrated that the two most 
robustly associated NAFLD variants (I148M in PNPLA3, the variant studied here, and E167K in 
TM6SF2) tracked with higher liver fat, higher risk for type 2 diabetes, but with lower serum 
triglycerides, lower serum low density lipoprotein (LDL) cholesterol and lower risk for CHD11.  
This apparent paradox might be explained if the variants chosen to index liver fat act by reducing very 
low density lipoprotein (VLDL) secretion from the liver. This would cause an accumulation of liver 
fat but a reduction in circulating triglycerides and LDL cholesterol, providing a potential explanation 
for the observed inverse genetic association of such variants with CHD12. Such an effect was also 
observed in treatment trials of the microsomal triglyceride transfer protein (MTP) inhibitor, 
lomitapide, which works by preventing liver secretion of VLDL, the precursor to LDL. Lomitapide, 
evaluated as treatment for patients with homozygous familial hypercholesterolaemia, reduces LDL 
cholesterol and triglycerides, but causes an elevation in serum transaminases and accumulation of 
hepatic fat13. MR analyses of NAFLD and CHD that utilise alternative genetic variants that index 
consequences of increased hepatic lipid influx (rather than reduced hepatic lipid efflux) would 
therefore be of interest. These might provide a closer biological proxy for the highly prevalent form of 
NAFLD that arises from an adverse diet and lifestyle. 
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The authors rightly address this and other limitations in their discussion. They also note that the 
findings may only be generalizable to individuals of European ancestry, since the genetic instrument 
was designed by using data from predominantly European studies. Only a single variant was used as a 
genetic instrument, accounting for a modest 1.1% variance in liver fat content. The large population 
sample (279,013 individuals) and its relatively high minor allele frequency allowed for an acceptable 
genetic instrument (with an F-statistic above the arbitrary cut-off of 10), however the possibility of 
weak-instrument bias (leading to false negative results) still remains. The exposure being 
instrumented genetically (liver fat content) is a fairly distal consequence of the unidirectional 
perturbation from genetic variation through to mRNA to protein and metabolome, making MR studies 
of such a trait more susceptible to horizontal pleiotropy (whereby the association of a genetic 
instrument with a disease end point is explained by a parallel association with a different exposure to 
the one of interest). The heritability of computer tomography (CT) measured hepatic steatosis has 
previously been estimated at 26%-27%14. In future, larger genetic studies with imaging, outcome and 
genotype data (e.g. UK Biobank) should permit much larger genome-wide association studies on liver 
imaging, allowing for the generation of more powerful and accurate genetic tools for MR analysis of 
both liver fat content and liver fibrosis15.  
In summary, Laurisden and colleagues8 confirm the observational association between liver fat 
content and CHD. When applying MR in a large population sample to investigate causality, this 
resulted in a negative study, suggesting that any association between liver fat content and CHD might 
not be causal. The availability of much larger studies with imaging, clinical outcome and genotype 
data will allow for more accurate and powerful genetic instruments for liver fat content (and 
potentially liver fibrosis), to further delineate the relationship between NAFLD and CHD. 
 
 
 
 
 5 
1.  Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of 
nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and 
outcomes. Hepatology. 2016 Jul;64(1):73–84.  
2.  Ekstedt M, Hagstr?m H, Nasr P, Fredrikson M, St?l P, Kechagias S, Hultcrantz R. Fibrosis 
stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of 
follow-up. Hepatology. 2015 May;61(5):1547–54.  
3.  Kim SU, Song D, Heo JH, Yoo J, Kim BK, Park JY, Kim DY, Ahn SH, Kim KJ, Han K-H, 
Kim YD. Liver fibrosis assessed with transient elastography is an independent risk factor for 
ischemic stroke. Atherosclerosis. 2017 May;260:156–62.  
4.  Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular 
disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013 Mar 19;10(6):330–44.  
5.  Sinn DH, Kang D, Chang Y, Ryu S, Gu S, Kim H, Seong D, Cho SJ, Yi B-K, Park H-D, Paik 
SW, Song Y Bin, Lazo M, Lima JAC, Guallar E, Cho J, Gwak G-Y. Non-alcoholic fatty liver 
disease and progression of coronary artery calcium score: a retrospective cohort study. Gut. 
2017;66(2):323–9.  
6.  Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P. 
Predicting cardiovascular risk in England and Wales: prospective derivation and validation of 
QRISK2. BMJ. 2008;336(7659):1475–82.  
7.  Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, 
Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, 
Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM, SCORE project group. 
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur 
Heart J. 2003;24(11):987–1003.  
8.  Lauridsen BK, Stender S, Kristensen T, Fuglsang KK, Kober L, Nordestgaard B, Tybjærg-
Hansen A. Liver fat content, NAFLD, and ischemic heart disease: Mendelian randomization 
and meta-analysis of 279,013 individuals. Eur Heart J. 2017; IN PRESS.  
9.  Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased 
survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 
2010;51(2):595–602.  
10.  Kahali B, Liu Y-L, Daly AK, Day CP, Anstee QM, Speliotes EK. TM6SF2: Catch-22 in the 
Fight Against Nonalcoholic Fatty Liver Disease and Cardiovascular Disease? 
Gastroenterology. 2015;148(4):679–84.  
11.  Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, Saleheen D, Emdin C, Alam 
D, Alves AC, Amouyel P, Di Angelantonio E, Arveiler D, Assimes TL, Auer PL, Baber U, 
Ballantyne CM, Bang LE, Benn M, Bis JC, Boehnke M, Boerwinkle E, Bork-Jensen J, 
Bottinger EP, Brandslund I, Brown M, Busonero F, Caulfield MJ, Chambers JC, Chasman DI, 
Chen YE, Chen Y-DI, Chowdhury R, Christensen C, Chu AY, Connell JM, Cucca F, Cupples 
LA, Damrauer SM, Davies G, Deary IJ, Dedoussis G, Denny JC, Dominiczak A, Dubé M-P, 
Ebeling T, Eiriksdottir G, Esko T, Farmaki A-E, Feitosa MF, Ferrario M, Ferrieres J, Ford I, 
Fornage M, Franks PW, Frayling TM, Frikke-Schmidt R, Fritsche LG, Frossard P, Fuster V, 
Ganesh SK, Gao W, Garcia ME, Gieger C, Giulianini F, Goodarzi MO, Grallert H, Grarup N, 
Groop L, Grove ML, Gudnason V, Hansen T, Harris TB, Hayward C, Hirschhorn JN, Holmen 
OL, Huffman J, Huo Y, Hveem K, Jabeen S, Jackson AU, Jakobsdottir J, Jarvelin M-R, Jensen 
GB, Jørgensen ME, Jukema JW, Justesen JM, Kamstrup PR, Kanoni S, Karpe F, Kee F, Khera 
A V, Klarin D, Koistinen HA, Kooner JS, Kooperberg C, Kuulasmaa K, Kuusisto J, Laakso 
M, Lakka T, Langenberg C, Langsted A, Launer LJ, Lauritzen T, Liewald DCM, Lin LA, 
Linneberg A, Loos RJF, Lu Y, Lu X, Mägi R, Malarstig A, Manichaikul A, Manning AK, 
 6 
Mäntyselkä P, Marouli E, Masca NGD, Maschio A, Meigs JB, Melander O, Metspalu A, 
Morris AP, Morrison AC, Mulas A, Müller-Nurasyid M, Munroe PB, Neville MJ, Nielsen JB, 
Nielsen SF, Nordestgaard BG, Ordovas JM, Mehran R, O’Donnell CJ, Orho-Melander M, 
Molony CM, Muntendam P, Padmanabhan S, Palmer CNA, Pasko D, Patel AP, Pedersen O, 
Perola M, Peters A, Pisinger C, Pistis G, Polasek O, Poulter N, Psaty BM, Rader DJ, Rasheed 
A, Rauramaa R, Reilly DF, Reiner AP, Renström F, Rich SS, Ridker PM, Rioux JD, 
Robertson NR, Roden DM, Rotter JI, Rudan I, Salomaa V, Samani NJ, Sanna S, Sattar N, 
Schmidt EM, Scott RA, Sever P, Sevilla RS, Shaffer CM, Sim X, Sivapalaratnam S, Small KS, 
Smith A V, Smith BH, Somayajula S, Southam L, Spector TD, Speliotes EK, Starr JM, 
Stirrups KE, Stitziel N, Strauch K, Stringham HM, Surendran P, Tada H, Tall AR, Tang H, 
Tardif J-C, Taylor KD, Trompet S, Tsao PS, Tuomilehto J, Tybjaerg-Hansen A, van Zuydam 
NR, Varbo A, Varga T V, Virtamo J, Waldenberger M, Wang N, Wareham NJ, Warren HR, 
Weeke PE, Weinstock J, Wessel J, Wilson JG, Wilson PWF, Xu M, Yaghootkar H, Young R, 
Zeggini E, Zhang H, Zheng NS, Zhang W, Zhang Y, Zhou W, Zhou Y, Zoledziewska M, 
Howson JMM, Danesh J, McCarthy MI, Cowan CA, Abecasis G, Deloukas P, Musunuru K, 
Willer CJ, Kathiresan S, Abecasis G, Deloukas P, Musunuru K, Willer CJ, Kathiresan S. 
Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet. 2017;doi: 
10.1038/ng.3977.  
12.  Holmes M V, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, Dale CE, 
Padmanabhan S, Finan C, Swerdlow DI, Tragante V, van Iperen EPA, Sivapalaratnam S, Shah 
S, Elbers CC, Shah T, Engmann J, Giambartolomei C, White J, Zabaneh D, Sofat R, 
McLachlan S, UCLEB consortium, Doevendans PA, Balmforth AJ, Hall AS, North KE, 
Almoguera B, Hoogeveen RC, Cushman M, Fornage M, Patel SR, Redline S, Siscovick DS, 
Tsai MY, Karczewski KJ, Hofker MH, Verschuren WM, Bots ML, van der Schouw YT, 
Melander O, Dominiczak AF, Morris R, Ben-Shlomo Y, Price J, Kumari M, Baumert J, Peters 
A, Thorand B, Koenig W, Gaunt TR, Humphries SE, Clarke R, Watkins H, Farrall M, Wilson 
JG, Rich SS, de Bakker PIW, Lange LA, Davey Smith G, Reiner AP, Talmud PJ, Kivimäki M, 
Lawlor DA, Dudbridge F, Samani NJ, Keating BJ, Hingorani AD, Casas JP. Mendelian 
randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36(9):539–50.  
13.  Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki 
K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of Microsomal Triglyceride Transfer 
Protein in Familial Hypercholesterolemia. N Engl J Med. 2007;356:148–56.  
14.  Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, 
Eiriksdottir G, Garcia ME, Launer LJ, Nalls MA, Clark JM, Mitchell BD, Shuldiner AR, 
Butler JL, Tomas M, Hoffmann U, Hwang S-J, Massaro JM, O’Donnell CJ, Sahani D V., 
Salomaa V, Schadt EE, Schwartz SM, Siscovick DS, Voight BF, Carr JJ, Feitosa MF, Harris 
TB, Fox CS, Smith A V., Kao WHL, Hirschhorn JN, Borecki IB, Kao WHL, Hirschhorn JN, 
Borecki IB, GOLD Consortium. Genome-Wide Association Analysis Identifies Variants 
Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic 
Traits. McCarthy MI, editor. PLoS Genet. 2011;7(3):e1001324.  
15.  Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, 
Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, 
Collins R. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide 
Range of Complex Diseases of Middle and Old Age. PLOS Med. 2015;12(3):e1001779.  
  
 7 
Figure 1. 
 
A) The Mendelian randomization (MR) model: the causal role of an exposure (e.g. CT liver fat 
content as a proxy for NAFLD) on a disease (e.g. CHD) is being examined. A genetic variant (e.g. 
IL4M) is robustly associated with the exposure (continuous arrow) but not with measured or 
unmeasured confounders (dotted arrow). The genetic variant is also associated with the disease only 
through its effects on the exposure and not directly (dotted arrow). The model rests on three 
assumptions: (i) the genetic instrument is associated with the exposure or biomarker of interest (ii) the 
genetic instrument must not associate with confounders that are either known or unknown; (iii) the 
outcome is associated with the genetic instrument only through the effect of the exposure, and is in all 
other respects independent.  
 
B) Summary figure of how MR can be considered analogous of the classical randomized controlled 
trial (RCT) (“treatment arms” shown in brackets) in the study by Lauridsen and colleagues8. Random 
allocation of alleles at conception and the unidirectional flow of information from the germline 
genome to exposure allow causal inference similar to the RCT framework. Genotype is generally 
unrelated to environmental exposure, thus reducing confounding. 
 
